Corbus Pharmaceuticals Holding (CRBP)vsVertex Pharmaceuticals Inc (VRTX)
CRBP
Corbus Pharmaceuticals Holding
$3.38
-0.44%
HEALTHCARE · Cap: $69.86M
VRTX
Vertex Pharmaceuticals Inc
$537.79
-0.15%
HEALTHCARE · Cap: $137.57B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 30.7% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 58/100 (C).
CRBP
Avoid28
out of 100
Grade: F
VRTX
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CRBP.
Margin of Safety
+44.9%
Fair Value
$977.14
Current Price
$537.79
$439.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 37.8%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 39.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : CRBP
The strongest argument for CRBP centers on Price/Book, Debt/Equity.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 30.7% and operating margin at 37.8%. Revenue growth of 11.8% demonstrates continued momentum.
Bear Case : CRBP
The primary concerns for CRBP are EPS Growth, Market Cap, Profit Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CRBP profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
CRBP carries more volatility with a beta of 2.79 — expect wider price swings.
VRTX is growing revenue faster at 11.8% — sustainability is the question.
VRTX generates stronger free cash flow (546M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (58/100 vs 28/100), backed by strong 30.7% margins and 11.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Corbus Pharmaceuticals Holding
HEALTHCARE · BIOTECHNOLOGY · USA
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. The company is headquartered in Norwood, Massachusetts.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?